A new study of an existing drug for immune disorders that may have positive effects for Alzheimer’s patients has attracted national attention lately. While phase III clinical trial results for Gammagard, an IVIG or “intravenous immunoglobulin therapy” by Baxter International are not expected until early 2013, hope for success must be balanced with a hard look at the data. The Wall Street Journal’s story on this drug and the prognosis for success by Dr. Rudy Tanzi of Massachusetts General Hospital and Harvard Medical School and Chair of Cure Alzheimer’s Fund’s Research Consortium and others is provided through the link below.
Promising Study Suggests That a Drug for Immune Disorders May Offer Benefits to Alzheimer's Patients
Posted: Jul. 25, 2012
© 2005-2017 Cure Alzheimer's Fund. All rights reserved.